tradingkey.logo

Exact Sciences Corp

EXAS
67.030USD
-0.720-1.06%
Cierre 11/14, 16:00ETCotizaciones retrasadas 15 min
12.70BCap. mercado
PérdidaP/E TTM

Exact Sciences Corp

67.030
-0.720-1.06%

Más Datos de Exact Sciences Corp Compañía

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Información de Exact Sciences Corp

Símbolo de cotizaciónEXAS
Nombre de la empresaExact Sciences Corp
Fecha de salida a bolsaJan 30, 2001
Director ejecutivoMr. Kevin T. Conroy
Número de empleados6900
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 30
Dirección5505 Endeavor Lane
CiudadMADISON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal53719
Teléfono16082845700
Sitio Webhttps://www.exactsciences.com/
Símbolo de cotizaciónEXAS
Fecha de salida a bolsaJan 30, 2001
Director ejecutivoMr. Kevin T. Conroy

Ejecutivos de Exact Sciences Corp

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.14M
-20.54%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
60.76K
-16.49%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+18.67%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
28.90K
+22.97%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
23.04K
-11.04%
Ms. Leslie L. Trigg
Ms. Leslie L. Trigg
Independent Director
Independent Director
17.17K
+80.75%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
16.38K
+156.47%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
13.84K
--
Mr. Michael J. (Mike) Barber, M.D.
Mr. Michael J. (Mike) Barber, M.D.
Independent Director
Independent Director
13.14K
+121.18%
Mr. James E. Doyle
Mr. James E. Doyle
Lead Independent Director
Lead Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.14M
-20.54%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
60.76K
-16.49%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+18.67%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
28.90K
+22.97%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
23.04K
-11.04%
Ms. Leslie L. Trigg
Ms. Leslie L. Trigg
Independent Director
Independent Director
17.17K
+80.75%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Commercial
387.50M
47.78%
Medicare Parts B & C
274.49M
33.84%
Other
93.84M
11.57%
International
55.26M
6.81%
Por regiónUSD
Nombre
Ganancia
Proporción
United States (Country)
755.83M
93.19%
Outside of united states
55.26M
6.81%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Commercial
387.50M
47.78%
Medicare Parts B & C
274.49M
33.84%
Other
93.84M
11.57%
International
55.26M
6.81%

Estadísticas de accionistas

Actualizado: hace 23 horas
Actualizado: hace 23 horas
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.38%
Capital World Investors
8.52%
Fidelity Management & Research Company LLC
8.12%
BlackRock Institutional Trust Company, N.A.
3.78%
Wellington Management Company, LLP
2.81%
Otro
67.40%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.38%
Capital World Investors
8.52%
Fidelity Management & Research Company LLC
8.12%
BlackRock Institutional Trust Company, N.A.
3.78%
Wellington Management Company, LLP
2.81%
Otro
67.40%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
52.84%
Investment Advisor/Hedge Fund
26.25%
Hedge Fund
6.43%
Pension Fund
2.25%
Research Firm
2.03%
Individual Investor
0.91%
Bank and Trust
0.56%
Sovereign Wealth Fund
0.48%
Private Equity
0.32%
Otro
7.92%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
1362
183.28M
96.81%
-19.18M
2025Q2
1403
202.48M
106.98%
+2.53M
2025Q1
1424
199.78M
106.03%
-445.52K
2024Q4
1411
200.72M
108.09%
-225.66K
2024Q3
1375
190.82M
103.28%
-5.17M
2024Q2
1358
185.25M
100.40%
+6.59M
2024Q1
1347
168.41M
92.78%
-6.10M
2023Q4
1356
165.31M
91.41%
-11.01M
2023Q3
1337
167.70M
92.83%
-6.22M
2023Q2
1354
166.38M
92.24%
-10.65M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
17.87M
9.44%
+303.00K
+1.73%
Jun 30, 2025
Capital World Investors
18.20M
9.61%
+364.75K
+2.05%
Jun 30, 2025
Fidelity Management & Research Company LLC
23.28M
12.3%
-852.45K
-3.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
7.04M
3.72%
-640.89K
-8.35%
Jun 30, 2025
Wellington Management Company, LLP
12.00M
6.34%
-497.53K
-3.98%
Jun 30, 2025
State Street Investment Management (US)
5.38M
2.84%
-1.23M
-18.67%
Jun 30, 2025
MFS Investment Management
2.96M
1.57%
+1.46M
+97.24%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.24M
1.71%
-29.40K
-0.90%
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
First Trust Nasdaq Lux Digi Health Solutions ETF
3.78%
First Trust NYSE Arca Biotechnology Index Fund
3.27%
Invesco Biotechnology & Genome ETF
3.17%
Alger Mid Cap 40 ETF
2.49%
First Trust Indxx Medical Devices ETF
2.34%
SPDR S&P Biotech ETF
2.06%
iShares Health Innovation Active ETF
1.84%
Franklin Genomic Advancements ETF
1.81%
ROBO Global Healthcare Technology & Innovation ETF
1.74%
VanEck Biotech ETF
1.44%
Ver más
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción3.78%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.27%
Invesco Biotechnology & Genome ETF
Proporción3.17%
Alger Mid Cap 40 ETF
Proporción2.49%
First Trust Indxx Medical Devices ETF
Proporción2.34%
SPDR S&P Biotech ETF
Proporción2.06%
iShares Health Innovation Active ETF
Proporción1.84%
Franklin Genomic Advancements ETF
Proporción1.81%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.74%
VanEck Biotech ETF
Proporción1.44%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI